10x Genomics Stock EBITDA
| TXG Stock | USD 26.29 0.63 2.34% |
10X Genomics fundamentals help investors to digest information that contributes to 10X Genomics' financial success or failures. It also enables traders to predict the movement of 10X Stock. The fundamental analysis module provides a way to measure 10X Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 10X Genomics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -158.2 M | -150.3 M |
10X | EBITDA |
10X Genomics Company EBITDA Analysis
10X Genomics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current 10X Genomics EBITDA | (158.25 M) |
Most of 10X Genomics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
10X EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for 10X Genomics is extremely important. It helps to project a fair market value of 10X Stock properly, considering its historical fundamentals such as EBITDA. Since 10X Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 10X Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 10X Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
10X Ebitda
Ebitda |
|
According to the company disclosure, 10X Genomics reported earnings before interest,tax, depreciation and amortization of (158.25 Million). This is 118.04% lower than that of the Life Sciences Tools & Services sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 104.06% higher than that of the company.
10X EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X Genomics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X Genomics could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics of similar companies.10X Genomics is currently under evaluation in ebitda category among related companies.
10X Genomics Institutional Holders
Institutional Holdings refers to the ownership stake in 10X Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 10X Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 10X Genomics' value.| Shares | Sumitomo Mitsui Trust Holdings Inc | 2023-12-31 | 2.3 M | Venrock Management Vi Llc | 2023-12-31 | 2.1 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | State Street Corporation | 2023-12-31 | 1.6 M | Rtw Investments, Llc | 2023-12-31 | 1.5 M | Generation Investment Management Llp | 2023-12-31 | 1.5 M | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Bp Wealth Management, Llc | 2023-12-31 | 1.4 M | Point72 Asset Management, L.p. | 2023-09-30 | 1.3 M | Fmr Inc | 2023-12-31 | 12.8 M | Vanguard Group Inc | 2023-12-31 | 9 M |
10X Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 2.94 B | ||||
| Shares Outstanding | 105.65 M | ||||
| Shares Owned By Insiders | 2.36 % | ||||
| Shares Owned By Institutions | 94.76 % | ||||
| Number Of Shares Shorted | 8.87 M | ||||
| Price To Book | 5.56 X | ||||
| Price To Sales | 6.65 X | ||||
| Revenue | 618.73 M | ||||
| Gross Profit | 396.02 M | ||||
| EBITDA | (158.25 M) | ||||
| Net Income | (255.1 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 95.37 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 6.00 X | ||||
| Cash Flow From Operations | (15.2 M) | ||||
| Short Ratio | 7.00 X | ||||
| Earnings Per Share | (2.24) X | ||||
| Price To Earnings To Growth | 0.13 X | ||||
| Target Price | 52.5 | ||||
| Number Of Employees | 1.26 K | ||||
| Beta | 1.89 | ||||
| Market Capitalization | 3.22 B | ||||
| Total Asset | 965.14 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 468.86 M | ||||
| Net Asset | 965.14 M |
About 10X Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out 10X Genomics Piotroski F Score and 10X Genomics Altman Z Score analysis. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is 10X Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.24) | Revenue Per Share 5.296 | Quarterly Revenue Growth 0.05 | Return On Assets (0.13) | Return On Equity (0.35) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.